Cyproterone Acetate + Ethinyl Estradiol

Introduction

Cyproterone Acetate and Ethinyl Estradiol are combined in a formulation used primarily for hormonal contraception and the treatment of various endocrine-related conditions. Cyproterone Acetate is an anti-androgen and progestin, while Ethinyl Estradiol is a synthetic estrogen. This combination is used in oral contraceptive pills and other hormonal therapies.

Uses

The combination of Cyproterone Acetate and Ethinyl Estradiol is used for:

Hormonal contraception to prevent pregnancy.
Treatment of severe acne in women, particularly when other treatments have failed.
Treatment of hirsutism (excessive hair growth) in women.
Management of endometriosis and other conditions related to excess androgens.

This combination is often found in oral contraceptive pills, sometimes in formulations designed for specific indications beyond pregnancy prevention.

Brand Name	Cyproterone Acetate + Ethinyl Estradiol
Type
Weight
Generic	Cyproterone Acetate + Ethinyl Estradiol
Manufacturer
Available in	English বাংলা

Mechanism of Action

The combination works through the following mechanisms:

Cyproterone Acetate: Acts as an anti-androgen by blocking androgen receptors and reducing androgen production. It also has progestational activity that inhibits ovulation.
Ethinyl Estradiol: Acts as a synthetic estrogen, stabilizing the endometrial lining and regulating the menstrual cycle. It also contributes to the inhibition of ovulation and alters the cervical mucus to prevent sperm penetration.

Together, these hormones provide effective contraception and address conditions related to excess androgens.

How Long Does It Take to Work?

For contraception, the effectiveness typically begins after 7 days of continuous use, or immediately if started during the first 5 days of the menstrual cycle. For other conditions, improvement may be observed within a few weeks, but full effects may take several months of consistent use.

Absorption

Both Cyproterone Acetate and Ethinyl Estradiol are well-absorbed from the gastrointestinal tract when taken orally. Peak plasma concentrations are generally reached within 1-2 hours after administration of a dose.

Route of Elimination

The hormones are primarily metabolized by the liver. They are excreted mainly in the urine, with a small amount eliminated in the feces. The metabolites are conjugated and subsequently excreted as glucuronides or sulfates.

Dosage

This tablet should not be prescribed solely for its contraceptive properties. If patient compliance is uncertain and contraception is necessary, then a supplementary nonhormonal contraceptive method should be considered.

First Treatment Course: The patient is instructed to take 1 tablet daily for 21 consecutive days beginning on day 1 of her menstrual cycle. (For the first cycle only the first day of menstrual flow is considered Day 1). The tablets are then discontinued for 7 days (1 week). Withdrawal bleeding should usually occur during the period that the patient is off the tablets.The first cycle will be somewhat shorter than usual, whereas all following cycles will last 4 weeks. The patient should be instructed to take the first tablet from the blister pack out of the section marked with the corresponding day (for example "Mon" for Monday) of the week and swallow it with some liquid. The patient should be instructed to take the tablet at the same time each day.

Subsequent Courses: The patient begins her next and all subsequent 21-day course of tablets (following the same 21 days on, 7 days off) on the same day of the week that she began her first course. She begins taking her tablets 7 days after discontinuation,regardless of whether or not withdrawal bleeding is still in progress.

Treatment should be continued for several months,since improvement may not be observed for at least 3 months. The need to continue treatment with This tablet should be evaluated periodically by the treating physician. This drug should be discontinued 3 to 4 cycles after signs have completely resolved.

Pregnancy should be ruled out before continuing treatment with This tablet in patients who have missed a menstrual period, if pregnancy is suspected, medication should be discontinued.

Missed dose: If the patient forgets to take a tablet at the usual time, the tablet may be taken within the next 12 hours. If more than 12 hours have elapsed from the time of usual administration, the patient must discard the missed tablet and continue to take the remaining tablets in the pack at the usual time in order to avoid premature withdrawal bleeding during this cycle. A supplementary nonhormonal method of contraception must be employed until the pack is empty to prevent pregnancy which would necessitate immediate discontinuation of this treatment.

Typical dosage for contraception and treatment of related conditions includes:

For hormonal contraception: 1 tablet daily, taken at the same time each day.
For acne or hirsutism: Dosage is similar to contraceptive use, with adjustments made based on individual response and tolerability.

Always follow the specific dosage instructions provided by a healthcare provider or as indicated on the prescription label.

Administration

These medications are usually administered orally in the form of tablets. It is important to take the tablets at the same time each day to maintain effective hormone levels. For contraceptive use, a standard regimen involves taking one tablet daily for 21 days, followed by a 7-day break or placebo period.

Side Effects

Common side effects may include:

Nausea or vomiting.
Headaches or migraines.
Breast tenderness.
Weight gain or fluid retention.
Changes in mood or libido.

Serious side effects may include blood clots, liver disorders, or severe allergic reactions. Contact a healthcare provider if severe symptoms occur.

Toxicity

Acute toxicity is rare with normal use. Overdose or prolonged high doses may lead to symptoms such as severe nausea, vomiting, dizziness, or liver dysfunction. Seek medical attention if an overdose is suspected.

Precautions

Precautions include:

Monitor for signs of thromboembolic events, especially in smokers or those with a history of blood clots.
Evaluate liver function regularly if long-term use is necessary.
Discontinue use and consult a healthcare provider if pregnancy is suspected or if severe side effects occur.

Ensure regular follow-ups with a healthcare provider for monitoring and management.

Interaction

Drug interactions may occur with:

Antibiotics and anticonvulsants that may reduce the effectiveness of the hormonal contraceptive.
Medications that affect liver enzymes, which may alter hormone levels and effectiveness.

Inform your healthcare provider of all medications and supplements being taken to avoid potential interactions.

Disease Interaction

Use with caution in individuals with:

Liver disease or history of liver disorders.
History of thromboembolic events or cardiovascular conditions.
Diabetes or hypertension, as these conditions may be exacerbated by hormonal changes.

Regular monitoring is advised for patients with these conditions.

Drug Interaction

Potential drug interactions include:

Rifampin and other enzyme inducers that may reduce effectiveness.
Antiretroviral drugs that may alter hormone metabolism.

Always consult a healthcare provider before combining with other medications.

Food Interactions

There are no significant food interactions with Cyproterone Acetate and Ethinyl Estradiol. However, alcohol and high-fat meals may affect drug metabolism and effectiveness. It is advisable to maintain a balanced diet and consult a healthcare provider regarding any specific dietary concerns.

Pregnancy Use

This combination is contraindicated during pregnancy. Hormonal contraceptives should be discontinued if pregnancy is suspected or confirmed. Consult a healthcare provider for alternative contraceptive methods during pregnancy.

Lactation Use

Use during lactation is generally not recommended as it may affect milk production and the infant. If necessary, consult with a healthcare provider to weigh the risks and benefits and to explore alternative options.

Acute Overdose

Acute overdose may lead to symptoms such as nausea, vomiting, and hormonal disturbances. Seek immediate medical attention if an overdose is suspected. Treatment generally focuses on symptomatic management and supportive care.

Contraindication

Contraindications include:

Pregnancy.
Active or history of thromboembolic disorders.
Severe liver disease.
Known or suspected breast cancer or estrogen-dependent tumors.

Avoid use in these conditions to prevent adverse effects and ensure safety.

Use Direction

Follow the prescribed dosage and regimen exactly. Take tablets at the same time each day and adhere to the schedule for 21 days followed by a 7-day break or placebo. Consult with a healthcare provider if any dose is missed or if there are concerns about adherence.

Storage Conditions

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children and ensure the container is tightly closed when not in use.

Volume of Distribution

The volume of distribution for Cyproterone Acetate and Ethinyl Estradiol is not extensively detailed in typical clinical settings. These compounds are distributed throughout the body and bind to plasma proteins, with effective concentrations maintained in the target tissues.

Half Life

The half-lives are approximately:

Cyproterone Acetate: 1-2 hours, with clinical effects persisting longer due to binding to tissues and receptors.
Ethinyl Estradiol: 13-27 hours, with steady-state levels achieved after several days of consistent dosing.

The half-lives may vary based on individual metabolism and health conditions.

Clearance

The clearance of these hormones is primarily through hepatic metabolism, with metabolites excreted in the urine. The rate of clearance can be influenced by liver function and other factors affecting drug metabolism.

See in details version Cyproterone Acetate + Ethinyl Estradiol also Cyproterone Acetate + Ethinyl Estradiol in bangla